
FDA Regulatory Books and PCR Memoirs: End-of-Summer Picks with Nick and Nigel
In this Bio Break episode, Nick Allan and Nigel Syrotuck share their end-of-summer reading list, featuring FDA regulatory books and PCR memoirs. From navigating regulatory hurdles to celebrating groundbreaking discoveries, their choices show how science reading can be both educational and entertaining.
FDA Regulatory Reading
Nigel highlights Innovation Breakdown, a book that examines the regulatory processes of the FDA. He explains that while the FDA ensures medical devices are safe and effective, the pathway to approval can be costly and complex. For innovators, this book illustrates both the challenges and safeguards within the FDA system.
PCR Discovery Through Storytelling
Nick’s pick is Dancing Naked in the Minefield by Kary Mullis. This memoir tells the story of polymerase chain reaction (PCR), a discovery that transformed molecular diagnostics. Mullis’s unusual personality and candid storytelling make the book as engaging as it is informative. PCR continues to influence lab testing worldwide, and Nick reflects on its lasting importance.
End-of-Summer Science Picks
Together, Nick and Nigel offer a mix of perspectives: FDA regulatory books that reveal systemic barriers and protections, and scientific memoirs that celebrate creativity and discovery. Their end-of-summer picks capture how reading can deepen our understanding of both process and innovation.
From FDA regulations to PCR breakthroughs, these end-of-summer reads show how science books can spark insight and inspiration.
Enjoying Bio Break? Sign up to get new episodes sent to your inbox.
Related Resources

Graphical mind maps created in online whiteboards offer a low-barrier, highly collaborative approach to early risk analysis in medical device development.

Early phase concept development is a weird part of a project lifecycle. It is often the most exciting phase, because the team is exploring possibilities, generating new ideas, and turning a fuzzy opportunity into something real.

Clinical prototypes must not only function as intended, but also be manufactured, documented, and supported in a way that satisfies regulatory expectations and clinical realities.

In this Bio Break episode, Nick and Nigel explore why some GLP-1 drugs are taken daily while others last a full week, and what drives that difference at a molecular level.